BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.
To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.
To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.
Reprints
Prescription drug rebates from drugmakers to commercial health insurers are steadily increasing due to the involvement of pharmacy benefit managers, according to a study published in JAMA Health Forum, reports Axios. Drugmakers’ contracts with PBMs and health plans can ultimately "incentivize drug manufacturers to inflate list prices and PBMs to distort drug formularies to favor high list price and high-rebate therapies, the study’s authors write. The issue has been gaining attention on Capitol Hill, with a bipartisan group of lawmakers pushing to outlaw rebates.
1. FTC refunds customers for fraudulent health plans sold by Benefytt
2. Health systems consider dropping Medicare Advantage plans due to financial losses
3. UnitedHealth faces rising lawsuits following Change Healthcare cyberattack
4. MedPAC calls for 'major overhaul' of Medicare Advantage policies
5. Medicare to cover Novo Nordisk's weight-loss drug for heart patients
6. AT&T faces second lawsuit over $8 billion pension risk transfer